Euglycemic hyperinsulinemia evokes both sympathetic activation and vasodilation in skeletal muscle, but the mechanism remains unknown. To determine whether insulin per se or insulin-induced stimulation ofcarbohydrate metabolism is the main excitatory stimulus, we performed, in six healthy lean subjects, simultaneous microneurographic recordings of muscle sympathetic nerve activity, plethysmographic measurements of calf blood flow, and calorimetric determinations of carbohydrate oxidation rate. Measurements were made during 2 h of: (a) insulin/glucose infusion (hyperinsulinemic 16 pmol/kg per min] euglycemic clamp), (b) exogenous glucose infusion at a rate matched to that attained during protocol a, and (c) exogenous fructose infusion at the same rate as for glucose infusion in protocol b. For a comparable rise in carbohydrate oxidation, insulin/glucose infusion that resulted in twofold greater increases in plasma insulin concentrations than did glucose infusion alone, evoked twofold greater increases in both muscle sympathetic nerve activity and calf blood flow. Fructose infusion, which increased carbohydrate oxidation comparably, but had only a minor effect on insulinemia, did not stimulate either muscle sympathetic nerve activity or calf blood flow. These observations suggest that in humans hyperinsulinemia per se, rather than insulin-induced stimulation of carbohydrate metabolism, is the main mechanism that triggers both sympathetic activation and vasodilation in skeletal muscle. (J. Clin. Invest. 1993. 92:147-154.) Key words: energy expenditure * fructose infusion * glucose infusion * microneurography -hyperinsulinemic euglycemic clamp
Introduction
Insulin, apart from its effects on intermediary metabolism, also has effects on the heart and the peripheral vasculature ( 1-4). For example, in humans acute euglycemic hyperinsulinemia stimulates both sympathetic efferent activity (5) (6) (7) (8) (9) , and blood flow in skeletal muscle (6, 9, 10) . More recently, evidence has accumulated in humans, indicating that insulin's cardiovascular effects may be involved in metabolic regulation (10, 11 ) . Insulin-induced stimulation ofblood flow to skeletal muscle, a major insulin-sensitive tissue, has been found to be closely correlated with insulin-mediated muscle glucose uptake. However, the mechanism by which insulin stimulates sympathetic activity and blood flow in skeletal muscle remains unknown. More specifically, it is not known whether such stimulatory effects are caused by hyperinsulinemia per se or hyperinsulinemia-induced stimulation of carbohydrate metabolism.
Accordingly, the purpose of this study was to determine whether hyperinsulinemia or carbohydrate metabolism is the primary stimulus that triggers sympathetic activation and vasodilation in humans. To accomplish this aim, we performed simultaneous microelectrode recordings of sympathetic nerve discharge to skeletal muscle, plethysmographic measurements ofcalfblood flow, and calorimetric determinations ofcarbohydrate oxidation in lean, healthy volunteers during euglycemic hyperinsulinemic glucose clamp, and exogenous glucose or fructose infusion. These interventions evoke comparable increases in carbohydrate oxidation but different increases in plasma insulin concentrations.
Methods

Subjects
Six lean, healthy subjects (wt 70.8±4.3 kg, height 180.2±5.3 cm, body mass index 21.8±0.8 kg/m2, age 28±4 yr, mean±SE) participated in this study after providing informed written consent. All subjects were normotensive, had normal glucose tolerance, were taking no medications, and had no evidence ofmetabolic or cardiovascular disease at the time of the study. Tests were performed within an interval of 5-8 wk, and were all conducted in the morning after an overnight fast. Subjects had been on a weight maintaining diet containing at least 40% carbohydrates for 3 d before the tests. The experimental protocol was approved by the Institutional Review Board on Human Investigation.
General procedures
Subjects were studied in the supine position. Heart rate (electrocardiogram), respiratory excursions (pneumobelt), blood pressure (Finapres blood pressure monitor; Ohmeda, Englewood, CO [12] ), calf blood flow (venous occlusion plethysmography [13] ), and efferent muscle sympathetic nerve activity (MSNA),' were recorded continuously on an electrostatic recorder and on a tape recorder (R7 1; TEAC Corp., Tokyo, Japan). Respiratory excursions were monitored to detect inadvertent performance of a Valsalva maneuver or prolonged expiration; these respiratory maneuvers can markedly stimulate MSNA ( 14) . Intravenous catheters were inserted in a right and a left antecubital vein, one for substrate infusion, the other for blood sampling. Urine was collected before and at the end ofthe study for nitrogen determination.
Experimental protocols
Protocol 1: hyperinsulinemic euglycemic clamp. After instrumentation and 1 h of baseline measurements, all six subjects received a primed continuous infusion of crystalline insulin (Actrapid HM; Novo Industri S/A, Bagsvaerd, Denmark) at a rate of 6 pmol/kg per min for 2 h. Euglycemia was maintained by determining plasma glucose concentration every 5 min and periodically adjusting a variable infusion of 20% dextrose ( 15) . Hypokalemia was prevented by administration of KC1 infused at a rate of 10 meq/h. Hemodynamic measurements and sympathetic nerve activity were recorded for 5 out ofevery 15 minthroughout the study. Blood samples were collected in the basal state and at timed intervals throughout the study for analysis of substrate and hormone concentrations.
Protocol 2: glucose infusion. All six subjects repeated the same protocol as above, except that instead of insulin, they received a continuous infusion of glucose for 2 h, at a rate matched to that observed during the last 30 min of the hyperinsulinemic euglycemic clamp.
Protocol 3:fructose infusion. Five ofthe six subjects participated in this protocol, during which they received a continuous infusion offructose for 2 h at a rate matched to that ofglucose observed during the last 30 min ofthe hyperinsulinemic euglycemic clamp. No KC1 was infused during this protocol.
Protocol 4: determination ofglucose oxidation duringfructose infusion. The rationale of these experiments, was to examine whether during fructose infusion, glucose oxidation contributes to the observed stimulation of carbohydrate oxidation. To address this issue, in six male lean healthy subjects (age 30±4 yr, body mass index 22.9±0.6 kg/iM2) after a bolus injection ofNaH '3CO3 (0.3 mmol), a prime ( 120 ,gg/kg)-continuous ( 
Calfbloodflow
Blood flow in the calfwas measured with venous occlusion plethysmography, using mercury-in-silastic strain gauges ( 13 ) . The calf was elevated 10-15 cm above the level ofthe right atrium to collapse the veins. The circulation to the foot was arrested by inflating a cuff around the ankles during blood flow determinations, which were performed at 15-s intervals for 5 min.
Indirect calorimetry
Energy expenditure and substrate utilization were calculated from respiratory gas exchanges (determined by a computerized, flowthrough canopy gas analyzer system [Deltatrac; Datex, Helsinki, Finland), and urinary nitrogen excretion, after correction for changes in the body urea nitrogen pool (17, 18 
Measurement ofglucose oxidation duringfructose infusion
Breath '3CO2 isotopic enrichment was measured by continuous-flow isotope ratio mass spectrometry (20) on a Roboprep G-Tracermass (Europa Scientific Ltd., Crewe, UK). Plasma samples (2 ml) were deproteinized with perchloric acid (3% final concentration), neutralized with 3.2 M K2CO3, and partially purified over sequential anioncation exchanger resins (AG 1-X8 and AG 50W-X8; Bio-Rad Laboratories, Richmond, CA). The neutral fraction was evaporated to dryness, resuspended in 140 ,l H20, and plasma glucose was purified by HPLC on a column (HPX-87-C; Bio-Rad Laboratories) eluted with H20 at a temperature of 80'C and at a flow rate of 0.6 ml/min. This procedure allows complete separation of plasma glucose from glycerol.
Purified glucose was again evaporated to dryness, resuspended in 15 ,ul H20, and its '3C enrichment was measured by combustion and continuous flow isotope ratio mass spectrometry on a Roboprep CN-Tracermass (Europa Scientific Ltd). Breath 13C02 and plasma ['3C]glucose were expressed as atom percent excess. Glucose oxidation was calculated as glucose oxidation (,umol/min) = { VCO2* '3COJ[ 13C]glucose * 0.8 }/0.134 where VCO2 is ml/min, and '3CO2 and ['3C]glucose are isotopic enrichments in atom percent excess. 0.134 ml CO2 is produced from oxidation of 1 tmol glucose. 0.8 is 13C02 recovery as determined previously in our laboratory (21) .
Analytical methods
Plasma glucose was determined in duplicate by the glucose oxidase method on a glucose analyzer (Beckman Instruments, Fullerton, CA), and plasma fructose by an enzymatic method (22) . Plasma insulin was measured by radioimmunoassay (23) , catecholamines by HPLC (24), blood urea nitrogen using a urea analyzer (Beckman Instruments), plasma free fatty acid concentrations by a colorimetric method using a kit from Wako (Freiburg, Germany), and urinary nitrogen by the Kjehldahl method (25) . 
Results
Plasma glucose, fructose, and insulin. Plasma glucose and insulin concentrations were comparable during the basal periods of all three protocols (Table I) . During the hyperinsulinemic euglycemic clamp the coefficient ofvariation in plasma glucose concentration was 4.3%. During glucose infusion, glucose concentrations nearly doubled and reached a plateau by the end of the first hour of infusion. During fructose infusion, plasma glucose concentrations remained stable, whereas plasma fructose concentrations rose from undetectable levels to 2.0±0.2 mmol/liter by the end of the first hour of infusion, and remained unchanged thereafter (Table I) .
As expected, the effects ofthe three experimental protocols on plasma insulin concentrations differed markedly (Table I , Fig. 1 ). During the euglycemic hyperinsulinemic clamp, plasma insulin concentrations rose more rapidly and to significantly (P < 0.05) higher levels than during glucose infusion (376.2±30.0 vs 282.6±19.8 pmol/liter). During fructose infusion, we observed only a minor, albeit statistically significant (P < 0.05) rise in plasma insulin concentrations from 37.2±1.9 to 57.0±2.7 pmol/liter. MSNA, calf blood flow, and calf vascular resistance. The 2-h euglycemic hyperinsulinemic clamp, which increased plasma insulin concentrations roughly tenfold above baseline, increased MSNA burst frequency by 93±18% and calf blood flow by 47±14%, whereas it decreased calf vascular resistance by 19±4% (Table I, Figs. 1 and 2 ). The 2-h infusion of exogenous glucose alone, which stimulated carbohydrate metabolism similarly as did insulin infusion, but increased plasma insulin concentrations only about half as much, also evoked twofold lesser (P < 0.05) increases of both MSNA burst frequency (54±10%), and calfblood flow (20±6%) ( Table I, Figs.  1 and 2 ). The 2-h infusion of fructose, which stimulated carbohydrate oxidation rate even more than did insulin/glucose or glucose infusion, but had only a minor effect on plasma insulin concentrations, had no effect on MSNA, calfblood flow, or calf vascular resistance (Table I, Figs. 1 and 2) . The latter finding is not caused by a nonspecific impairment of sympathetic outflow by fructose infusion, since sympathetic responses to a Valsalva maneuver were not altered by fructose infusion; peak sympathetic responses were 69±8 bursts/min during insulin/ glucose infusion, and 72±5 bursts/min during fructose infusion(P> 0.1).
During insulin/glucose infusion, not only the magnitude of the MSNA and calfblood flow responses was markedly greater, but also the latency in the onset of these responses was markedly shorter than during glucose infusion alone. MSNA and calf blood flow had increased significantly (P < 0.05) above baseline 45 min after the start of insulin/glucose infusion, but only 90 min after the start of glucose infusion (Fig. 1 ) .
During both insulin/glucose infusion and glucose infusion alone, there was a positive correlation between plasma insulin concentration and MSNA, calf blood flow, and carbohydrate oxidation. During insulin/glucose infusion, the r values for the correlation between insulin and MSNA, insulin and calfblood flow, and insulin and carbohydrate oxidation were 0.57 (P = 0.003), 0.42 (P = 0.02), and 0.57 (P = 0.001 ), respectively; during glucose infusion alone, the corresponding r values were 0.68 (P = 0.0002), 0.56 (P = 0.001), and 0.73 (P = 0.0001), respectively.
Plasma catecholamines andpotassium. During none ofthe three experimental protocols did plasma norepinephrine or epinephrine levels change significantly (Table I) . Serum potassium remained within the normal range during all three protocols. Plasma potassium concentrations at the end of the 2-h infusions of insulin/glucose, glucose, and fructose were 3.6±0.1, 3.9±0.1, and 3.9±0.1 mmol/liter, respectively.
Blood pressure and heart rate. In all three studies, systolic, diastolic, and mean arterial blood pressure remained unchanged throughout the protocol. In contrast, there was a small but significant (P < 0.05) increase in heart rate during the second hour in all three protocols (Table I) .
Carbohydrate metabolism and energy expenditure. In all three studies, carbohydrate oxidation increased similarly (Table II, Fig. 1 Figure 2 . Segments of illustrative recordings of MSNA from the same subject obtained during the last 5 min of 2-h infusions of each, insulin (euglycemic clamp), glucose, and fructose. On these mean voltage displays of MSNA, each peak represents a spontaneous burst of sympathetic discharge. For comparable rates ofcarbohydrate oxidation, insulin/glucose infusion, which in this subject increased plasma insulin concentration by 373 pmol/liter above baseline, evoked a much greater increase in MSNA than did glucose infusion alone, which increased plasma insulin concentration only by 253 pmol/liter. The recording obtained during the last 5 min offructose infusion, which had only a minor effect on plasma insulin concentration (+ 18 pmol above baseline), was superposable to the recording obtained during the basal period (not shown). whereas during glucose infusion, energy expenditure increased mostly during the second hour of infusion (Table II) .
Discussion
The respective roles played by hyperinsulinemia per se, and hyperinsulinemia-induced stimulation ofcarbohydrate metabolism, in the regulation of sympathetic outflow and blood flow in skeletal muscle have been difficult to elucidate using incremental insulin infusions (6) , and indirect indices of sympathetic nerve activity (26) . The cose infusion alone, also evoked twofold greater increases in MSNA and in calf blood flow. Furthermore, fructose infusion that increased carbohydrate oxidation to a rate similar to that observed during insulin/glucose infusion, but had only minor effects on insulinemia, did not stimulate either MSNA or calf blood flow. These findings provide evidence in humans that hyperinsulinemia per se is the main mechanism which triggers both sympathetic activation and vasodilation in a major insulin-sensitive tissue, skeletal muscle. This interpretation is predicated upon the assumption that the stimulation ofcarbohydrate metabolism indeed was comparable in the present experimental protocols. Plasma insulin concentrations such as those observed during the present insulin/glucose or glucose infusion studies, are known to completely suppress hepatic glucose production (27) ; thus, under these conditions, total glucose uptake is equal to exogenous glucose infusion. During fructose infusion at the rates used in the present experiments, endogenous glucose production is not suppressed ( 19) because fructose uptake and subsequent stimulation of carbohydrate metabolism occurs in the absence of hyperinsulinemia (28). Therefore, total carbohydrate uptake may have been slightly higher during fructose infusion than during insulin/glucose or glucose infusion. Thus, in the present experiments, similar stimulation of carbohydrate metabo- Carbohydrate oxidation measurements were determined using indirect calorimetry, and represent the average value of the last 30 min of control, and the last 30 min of fructose infusion, respectively. * P < 0.01 vs. corresponding basal period.
lism was associated with strikingly different degrees of sympathetic activation and vasodilation in skeletal muscle. There is abundant evidence that estimates of carbohydrate oxidation obtained by indirect calorimetry, and adjusted for changes in urea pool size, are highly reliable and reproducible (17, 18) . In the present studies, carbohydrate oxidation increased similarly in all three protocols to attain rates twofold above basal during the last 30 min of infusion. Kinetics of the increases in carbohydrate oxidation during the initial phase (i.e., the first 30 min) of insulin/glucose infusion and glucose infusion alone also were similar, as shown by analysis ofcalorimetric determinations ofcarbohydrate oxidation using 15-min time intervals, whereas kinetics of the increases in MSNA and blood flow differed markedly during the initial phase of these two experimental protocols.
Finally, several lines of evidence indicate that, even though during fructose infusion the initial step of fructose metabolism is mainly hepatic, skeletal muscle accounts for an important proportion of fructose disposal (29-3 1 ) . During fructose infusion in humans, muscle glycogen content in skeletal muscle biopsies increases similarly as during glucose infusion (29, 30) . This increase has been attributed in part to direct fructose uptake in skeletal muscle, as demonstrated both by determination ofarteriovenous fructose concentrations in human forearm tissue (32), and by direct measurements of splanchnic and renal substrate exchange during fructose infusion in humans, showing that 30-40% offructose disposal could not be accounted for by splanchnic or renal tissue and presumably was largely taking place in skeletal muscle (31). In addition, uptake oflactate and glucose, resulting from fructose-induced stimulation ofendogenous glucose production (31 ) and splanchnic and renal lactate release (31 ), may also contribute to stimulation of muscle metabolism. In this regard, our data provide direct evidence that fructose infusion in the amounts used in the present experiments is accompanied by a 22% increase in glucose oxidation. Thus, even though some of the precise steps involved in fructose metabolism are still unknown, there is agreement that a substantial part of this metabolism is taking place in skeletal muscle (33) . In the present studies, such stimulation ofmuscle carbohydrate metabolism during fructose infusion was not associated with sympathetic activation and vasodilation in skeletal muscle.
By comparing sympathetic and vasodilatory responses at the same metabolic endpoints in the same subjects, we were able to dissociate the effects ofcarbohydrate uptake, oxidation, and storage, from the effects ofhyperinsulinemia on the regulation of sympathetic outflow and blood flow in skeletal muscle. We found that during insulin/glucose infusion, MSNA and calf blood flow increased markedly already during the first hour of infusion. In contrast, during glucose infusion, nerve traffic and calfblood flow did not increase during the first hour of infusion but only during the second hour of infusion, when plasma insulin concentrations had more than doubled as compared to the first hour of infusion. The present findings suggest that this delayed pattern ofsympathetic activation and stimulation of blood flow during glucose infusion is related to the delayed increase in plasma insulin concentrations observed under these conditions. The studies using fructose infusion strengthen this interpretation by demonstrating that the stimulation of MSNA and muscle blood flow during insulin/glucose and glucose infusion is not an artifact caused, for example, by increasing discomfort of the subjects resulting in nonspecific sympathetic activation.
The present data represent the first demonstration in humans that not only insulin/glucose infusion, but also glucose infusion alone, stimulates sympathetic outflow to skeletal muscle. This conclusion differs from that of two previous studies in which intravenous administration of glucose had no detectable effect on sympathetic activity (5, 26) . However, the conclusions of one study were based upon the absence of a detectable effect of glucose infusion on plasma norepinephrine levels (5, 26), a relatively insensitive index of sympathetic discharge (34) (35) (36) . In the present study, infusion of exogenous glucose in amounts comparable to those used in this earlier study (26) also did not increase plasma norepinephrine levels significantly, but evoked highly significant increases in sympathetic discharge targeted at skeletal muscle. The other study used intravenous bolus injections of glucose, which caused only very short lasting increases in plasma insulin concentrations (5) that may have been insufficient to increase sympathetic outflow. Furthermore, these bolus injections resulted in acute volume expansion, which, in turn, could have reflexly decreased sympathetic outflow by stimulating inhibitory cardiopulmonary afferents (37) , thereby masking a potential sympathoexcitatory effect of such short lasting glucose-induced hyperinsulinemia.
Our interpretation, that during glucose infusion hyperinsulinemia is the primary stimulus not only for sympathetic activation, but also for vasodilation in skeletal muscle, is strengthened by the recent observation in humans that somatostatin administration during glucose infusion suppresses not only glucose-induced stimulation of endogenous insulin secretion, but vasodilation in skeletal muscle as well (38) .
This insulin-induced vasodilation may be of physiological importance. First, there is increasing evidence that stimulation ofblood flow to insulin-sensitive tissues during insulin/glucose and glucose infusion may be an important determinant of the rate of in vivo glucose uptake ( 10, 11, 38) . Second, a balance between insulin's opposing sympathoexcitatory pressor and vasodilatory depressor effects may offer a potential explanation for the present, and earlier (6, 7, 26) observations, that in lean healthy subjects acute hyperinsulinemia at high physiologic concentrations does not raise arterial pressure.
The present experiments in humans do not elucidate the underlying mechanisms of insulin-induced sympathetic activation and vasodilation. The present observation during insulin/glucose infusion, that MSNA and calf blood flow did not show a peak increase during the initial peak increase ofplasma insulin concentration, and showed a further increase when plasma insulin levels were at steady state, could suggest that insulin may have to reach the interstitial space to exert its excitatory effects. In this regard, findings during insulin infusion in dogs, showed a time lag between the steep initial increase in plasma insulin concentration and the appearance of insulin in the lymph, an indicator of interstitial insulin concentration, and-a further increase in lymph insulin concentrations when plasma insulin levels were decreasing or at steady state (39) . One potential mechanism by which insulin may exert its sympathoexcitatory effects, is that insulin-induced vasodilation in skeletal muscle may lead to slight decreases in arterial pressure and baroreflex mediated increases in MSNA. In this regard, an earlier study found a small but significant decrease in diastolic blood pressure during insulin/glucose infusion in humans (6) . Alternatively, a central neural action of insulin may also contribute to stimulation of sympathetic outflow in this setting (8, (40) (41) (42) (43) .
Insulin/glucose or glucose infusion in humans not only stimulates sympathetic activity and blood flow in skeletal muscle, but also increases energy expenditure by stimulating obligatory and facultative thermogenesis (44) . The latter has been thought to be sympathetically mediated because it can be suppressed by propranolol (44, 45) . Here, we provide direct evidence that insulin/glucose and glucose infusion indeed stimulate MSNA that, in turn, may contribute to the thermogenesis observed under these conditions. However, fructose infusion that increased thermogenesis even more than did insulin/glucose or glucose infusion (45), did not stimulate MSNA, and did not have any detectable effect on plasma norepinephrine levels. This is an unexpected finding, since it has been thought that fructose-induced thermogenesis also is sympathetically mediated, because it can be suppressed by beta-blocker administration (19, 46) . However, regional sympathetic responses can be highly differentiated (47) , and the present observations based upon direct measurements of sympathetic nerve action potentials targeted specifically at skeletal muscle, do not exclude the possibility of a fructose-induced stimulation of sympathetic outflow targeted at other tissues such as the liver which, in turn, may have contributed to thermogenesis.
In conclusion, these experimental findings in healthy humans suggest that hyperinsulinemia per se, rather than hyperinsulinemia-induced stimulation of carbohydrate metabolism, is the primary stimulus for both sympathetic activation and vasodilation in a major insulin-sensitive tissue, skeletal muscle. This vascular effect of insulin may be of physiological importance, as recent evidence indicates that insulin resistance is associated with attenuated hyperinsulinemia-induced vasodilation in skeletal muscle ( 10, 11) .
